Business Wire

GCCA

14.3.2023 14:02:00 CET | Business Wire | Press release

Share
Open Innovation Challenge Calls up Start-Ups in Drive Towards Net Zero Concrete

Start-ups from around the world can play a leading role in helping an essential global industry in its efforts to cut CO2 emissions and help solve the climate challenge. They are being invited to apply for the Innovandi Open Challenge, an exciting international partnership programme, run by the Global Cement and Concrete Association (GCCA) and its member companies across the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005357/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Applications for the 2023 GCCA Innovandi Open Challenge are now open (Graphic: Business Wire)

Applicants are being asked to work on the development of new materials and ingredients for low carbon concrete – a major step towards the ultimate goal of net zero concrete.

Innovation can help further unlock the delivery of low carbon concrete by reducing the amount of clinker used - the carbon intensive element of cement - or by using the most cutting-edge manufacturing processes. Alternative materials, including construction and demolition waste, can result in much lower CO2 emissions than concrete made in the traditional method, as well as reduce the need to use virgin raw materials.

The global challenge matches start-up companies with some of the world’s leading cement and concrete manufacturers, who operate in almost every country across the world, to work on initiatives to cut emissions and pioneer environmental change across the industry.

The GCCA and its members account for 80% of global cement production capacity outside of China, as well as some key Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete (which currently account for around 7% globally), through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.

The launch follows the success of last year’s first ever Innovandi Open Challenge, which saw cement companies partnering with six start-ups, with a strong focus on carbon capture and utilisation projects. Three of those projects have already gone to pilot stage.

Thomas Guillot, Chief Executive of the GCCA, said:

“We’re calling on the best and the brightest from around the world to join us in the urgent fight to limit global warming and help towards delivering the great prize of net zero concrete. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology, then we want to hear from you.”

“Concrete is the second most used substance on earth after water and is a vital part of our modern infrastructure. The GCCA and all our members are working hard to reduce emissions. And start-ups can play a big role in helping us to do that.”

Start-ups can find more information and apply to take part in the Innovandi Open Challenge by going to the GCCA Open Challenge webpage:

https://gccassociation.org/innovandi/openchallenge/oc2023

Those companies who are accepted for this year’s Innovandi Open Challenge, will gain unique access to industry plants, labs, key networks and the expertise and infrastructure of the GCCA’s 40 members from around the world. They will also receive guidance from the GCCA and its members to help them with the development of new technology and business cases.

Claude Loréa, GCCA Cement Director and Innovation Lead said:

“We’ve already seen some remarkable progress from those start-ups who’ve been working with our members on the first Innovandi Open Challenge, with several projects already in the pilot stage. This year’s theme, low carbon concrete, is equally challenging. To succeed, we need products which are affordable, scalable, and easily adopted. Good luck to all this year’s applicants. We look forward to working with those selected.”

Natalie Giglio is Senior Business Development Associate, at Carbon Upcycling Technologies in Canada, which took part in the first Innovandi Open Challenge. She encourages all start-ups interested in working on net-zero initiatives to apply:

"The Innovandi program is specifically designed to foster collaboration among the largest global cement producers, and start-ups, which is an opportunity unique to this challenge. Our initiative focused on validating materials at the lab scale, and now the results have set a foundation for further collaboration and project development.”

/ Ends

Notes to editors:

The Innovandi Open Challenge is open to applicants from 14th March 2023, with applications closing on 30th May 2023.

For more information click here:

Additional quotes from start-ups which have taken part in the 1st Innovandi Open Challenge:

Carbon BioCapture is based in the USA and has patented technology for CO2 capture using microalgae (microscopic algae invisible to the naked eye.) CEO Andrea Irarrazaval said: “It has been a great opportunity and an honour for Carbon BioCapture (CBC) to be selected in GCCA's Open Challenge global programme… Participation provides valuable means for tech start-ups to access, obtain growth assistance, and help to demonstrate their technology potential to the critical cement and concrete global industry."

CarbonOrO, based in the Netherlands, specializes in carbon capture technology using unique bi-phasic amine. Spokesperson Jan Hoppenbrouwers said: “There is a lot of talk about carbon capture, utilisation and storage but worldwide, we need to accelerate the number of pilots and move towards commercial scale roll-out. GCCA members and their consortia’s joined efforts have all the characteristics to change this. So, our advice, participate in this challenge.”

Coomtech based in the UK, has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture. Founder Chris Every said: “Coomtech took part in the Innovandi Open Challenge to showcase its technology at a global level to the cement and concrete industry. Innovandi has been highly supportive and is commercially attuned to new technologies. The connections the program makes are an excellent springboard for emerging technology businesses focused on the vital cement and concrete sector.”

Fortera, based in the USA, uses technology to capture CO2 emissions from cement plants, combining it with calcium oxide to make reactive calcium carbonate. Vice President Kas Farsad, said: “The Innovandi Open Challenge platform allowed Fortera to engage multiple cement players simultaneously and really dig into not just industry pain points, but brainstorm on solutions with the broader industry in mind. Whether you're looking to launch a pilot plant or to validate a commercial offering, you'll get a committed consortium of GCCA members supporting your process."

MOF Technologies, based in the UK, is using modern sorbents called metal-organic frameworks (MOFs) to engineer a filtration system to capture and remove CO2 from flue gas. Conor Hamill, Co-CEO said: “Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to have had the opportunity to collaborate with GCCA members to bring our technology to the field. We are currently working with an innovative consortium to pilot our ultra-efficient Nuada technology which will validate its potential to provide the industry with a scalable low-cost carbon capture solution.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005357/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye